Canaccord Genuity Reiterates a 'Buy' on Omeros Corp. (OMER); Key Takeaways From Expert Call Indicate Significant Market Opportunity
Tweet Send to a FriendGet Alerts OMER Hot Sheet
Price: $5.38 +0.75%
Rating Summary:
8 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Rating Summary:
8 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Trade OMER Now!
Canaccord Genuity reiterates a 'Buy' on Omeros Corp. (NASDAQ: OMER), PT $13.
Canaccord analyst says, "We recently hosted a call with a Dr. William Garrett, a leading orthopaedic surgeon, for an in-depth discussion of Omeros’s Phase 3 PharmacoSurgery program, with a focus on OMS103HP; we expect Phase 3 data in Q1/11. While the initial indication is arthroscopic anterior cruciate ligament (ACL) and meniscectomy, our expert believes that if positive, OMS103HP could enjoy use in other arthroscopic and other surgeries where pain and inflammation are issues."
For more ratings news on Omeros Corp. click here and for the rating history of Omeros Corp. click here.
Shares of Omeros Corp. closed at $7.03 yesterday, with a 52 week range of $5.02-$8.99.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Canaccord analyst says, "We recently hosted a call with a Dr. William Garrett, a leading orthopaedic surgeon, for an in-depth discussion of Omeros’s Phase 3 PharmacoSurgery program, with a focus on OMS103HP; we expect Phase 3 data in Q1/11. While the initial indication is arthroscopic anterior cruciate ligament (ACL) and meniscectomy, our expert believes that if positive, OMS103HP could enjoy use in other arthroscopic and other surgeries where pain and inflammation are issues."
For more ratings news on Omeros Corp. click here and for the rating history of Omeros Corp. click here.
Shares of Omeros Corp. closed at $7.03 yesterday, with a 52 week range of $5.02-$8.99.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
- UPDATE: BTIG Starts ING U.S (VOYA) at Buy, Shares 'Significantly Undervalued'
- Actavis (ACT) Fairly Valued After Run-Up - Jefferies
Create E-mail Alert Related Categories
Analyst Comments
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
